|
HER2-negative breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our transfluorinated analog ([<sup>18</sup>F]-CDKi) was evaluated and validated as a novel PET imaging agent to quantify CDK4/6 expression in ER-positive HER2-negative breast cancer.
|
31481582 |
2020 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data underscore the importance of CDK4/6 signaling in HR+/HER2‒ breast cancer and suggest that the interplay between steroid hormone and peptide growth factor signaling could drive dependence on CDK4/6 signaling.(Pfizer; NCT01740427).
|
31527167 |
2020 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selective CDK4/6 inhibitors specifically target a variety of tumors, with the main focus on hormone receptor(HR)-positive and human epidermal growth factor receptor 2(HER2)-negative breast cancer (BC).
|
31798393 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.
|
31832106 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK 4/6 inhibitors represent a valuable treatment option for patients with metastatic hormone receptor-positive HER2-negative breast cancer.
|
30520756 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer.
|
30867218 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting.
|
31151842 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We reviewed clinical trials investigating the efficacy of CDK4/6 inhibitors for advanced or metastatic HR+/HER2- breast cancer.
|
31695840 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the past four years, the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, received their first FDA approval for the treatment of Hormone Receptor (HR)-positive and Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer after showing significant improvements in progression-free survival in the PALOMA-1, MONALEESA-2 and the MONARCH-2 randomized clinical trials, respectively.
|
30959874 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by Federal Drug Administration and the European Medicines Agency for the treatment of advanced and metastatic HR+/HER2- breast cancer.
|
31777590 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three CDK4/6 inhibitors, palbociclib (PAL), ribociclib (RIB), and abemaciclib, when combined with letrozole (LET), have been approved as first-line therapy for postmenopausal women with metastatic HR+, HER2- breast cancer.
|
30847728 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elacestrant is a novel, nonsteroidal, orally bioavailable selective estrogen receptor degrader (SERD) that has demonstrated activity in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer previously treated with endocrine therapies including fulvestrant and/or CDK 4/6 inhibitor therapy, and in those with <i>ESR1</i> mutations (<i>ESR1</i>-mut) known to confer endocrine resistance.
|
31426673 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
|
30574210 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on the recent reports of the essential role of PI3K/Akt/mTOR and CDK4/6/RB pathways in ER+ HER2- breast cancer.
|
29086897 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CDK4/6 inhibitor palbociclib in combination with endocrine therapy has been approved for treatment of HR-positive/HER2-negative breast cancer patients.
|
30130984 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we performed a meta-analysis of randomized clinical trials (RCTs) to better define the benefit and the risk of CDK4/6 inhibitors plus ET for endocrine-sensitive or endocrine-resistant population in metastatic HR+/HER2- breast cancer.
|
30054831 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.
|
30479671 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adding the CDK4/6 inhibitor ribociclib to standard first-line endocrine therapy significantly prolonged survival in premenopausal and perimenopausal women with advanced HR-positive, HER2-negative breast cancer enrolled in the MONALEESA-7 trial.
|
29229752 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is approved for metastatic estrogen receptor (ER)-positive and human epithermal growth factor 2 (HER2)-negative breast cancer.
|
29261702 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
|
27564114 |
2016 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.
|
23776583 |
2013 |